ZTS
Zoetis Inc.
NYSE · Healthcare · Drug Manufacturers - Specialty & Generic · US
$71.45
−2.15%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$72.57
From 52W high−51.57%
Volume9.56M
Market cap$29.52B
P/E (TTM)11.8x
P/S (TTM)3.1x
Div yield1.48%
Key dataSep 18, 2026
Open
$72.57
From 52W high
−51.57%
Volume
9.56M
Market cap
$29.52B
ValuationView details →
P/E (Fwd)
11.5x
EV/EBITDA
9.6x
P/E (TTM)
11.8x
RSI (14)
40.2
MomentumView details →
1D Return
−2.15%
YTD Return
−42.32%
SummaryUpdated Jun 1, 2026
Zoetis Inc. (NYSE:ZTS) is the world's largest animal health company, founded in 1952 and spun off from Pfizer in 2013 through an initial public offering. Headquartered in Parsippany, New Jersey, the company has evolved from a pharmaceutical division into an independent leader in veterinary medicine, serving both companion animals and livestock across global markets. With operations spanning the United States and international markets, Zoetis has established itself as a dominant force in animal healthcare through decades of scientific innovation and strategic market expansion.
Similar companies
Latest newsMore news →
Zoetis (ZTS) shares closed at $71.40, down 2.22% from the prior trading session.2d agoThe U.S. Food and Drug Administration published in the Federal Register three Emergency Use Authorizations for animal drugs to treat or prevent New World screwworm, including the first injectable product listing deer, issued to Zoetis, Felix Pharmaceuticals, and Alberta Vet Labs.18d agoZoetis received emergency use authorization for its drug to treat screwworm, causing its stock price to rise.38d ago